Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B

Author： Hayashi Hidetoshi  

Publisher： Springer Publishing Company

ISSN： 1340-6868

Source： Breast Cancer, Vol.20, Iss.2, 2013-04, pp. : 131-136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer

By Ma Cynthia  

Breast Cancer Research and Treatment, Vol. 137, Iss. 2, 2013-01 ,pp. : 483-492

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer

By Ueno Hideki   Okusaka Takuji   Funakoshi Akihiro   Ishii Hiroshi   Yamao Kenji   Ishikawa Osamu   Ohkawa Shinichi   Saitoh Soh  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 4, 2007-03 ,pp. : 447-454

Springer Publishing Company

Access to resources Recommend Favorite

A Phase II NCCTG Study of Irinotecan and Docetaxel in Previously Treated Patients with Non-Small Cell Lung Cancer

By Molina Julian   Nikcevich Daniel   Hillman Shauna   Geyer Susan   Drevyanko Timothy   Jett James   Verdirame Joseph   Tazelaar Henry   Rowland Kendrith   Wos Edward   Kutteh Leila   Nair Suresh   Fitch Tom   Flynn Patrick   Stella Philip   Adjei Alex  

Cancer Investigation, Vol. 24, Iss. 4, 2006-07 ,pp. : 382-389

Informa Healthcare

Access to resources Recommend Favorite

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

By Lobo Christopher   Lopes Gilberto   Baez Odalys   Castrellon Aurelio   Ferrell Annapoorna   Higgins Connie   Hurley Erin   Hurley Judith   Reis Isildinha   Richman Stephen   Seo Pearl   Silva Orlando   Slingerland Joyce   Tukia Keleni   Welsh Catherine   Glück Stefan  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 427-435

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors

By Saif Muhammad   Sellers Sandra   Li Mao   Wang Wei   Cusimano Linda   Wang Hui   Zhang Ruiwen  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 6, 2007-11 ,pp. : 871-882

Springer Publishing Company

Access to resources Recommend Favorite